Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 4:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 470 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Coronary Stenosis Clear all

Conditions: Aortic Stenosis
Interventions: NT-pro-BNP levels; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
Interventions: SAPIEN 3/SAPIEN 3 Ultra RESILIA THV, SAPIEN 3 THV, SAPIEN 3 Ultra RESILIA THV; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2031
U.S. locations: 27
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Coronary Stenosis
Interventions: Not listed
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Obstructive Hypertrophic Cardiomyopathy
Interventions: Mavacamten, Non-mavacamten symptomatic oHCM therapy; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 60
States / cities: Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 48 more

Conditions: Williams Syndrome
Interventions: Vitamin D; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hypertrophic Cardiomyopathy
Interventions: Diltiazem, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 5 Years to 39 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease
Interventions: Intracoronary ECG; Procedure
Lead sponsor: University National Heart Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Inherited Cardiac Arrythmias, Long QT Syndrome (LQTS), Brugada Syndrome (BrS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Early Repolarization Syndrome (ERS), Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Normal Control Subjects
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Aortic Stenosis
Interventions: Portable 1-lead electrocardiogram, Point-of-care ultrasound, AI-ECG risk algorithm, AI-POCUS; Diagnostic Test · Other
Lead sponsor: Yale University; Other
Eligibility: 70 Years and older
Enrollment: 410 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: New Haven, Connecticut • New York, New York • Houston, Texas

Conditions: Aortic Valve Stenosis
Interventions: TAVR with CENTERA THV; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 23
States / cities: Los Angeles, California • Stanford, California • Loveland, Colorado + 19 more

Conditions: Aortic Stenosis
Interventions: Impedance Cardiography Upright/Supine Test; Device
Lead sponsor: Dermed Diagnostics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Aortic Valve Stenosis, Aortic Stenosis, Aortic Valve Disease
Interventions: EmStop Embolic Protection System, Boston Scientific Sentinel; Device
Lead sponsor: EmStop Inc; Industry
Eligibility: 22 Years and older
Enrollment: 663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Thousand Oaks, California • Clearwater, Florida • New Orleans, Louisiana + 4 more

Conditions: Aortic Valve Stenosis
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Unstable Angina, Coronary Atherosclerosis, Coronary Restenosis
Interventions: Serine proteinase-1 (Serp-1); Drug
Lead sponsor: Viron Therapeutics Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Gainesville, Florida • Grand Rapids, Michigan

Conditions: Pulmonary Vein Stenosis
Interventions: Standardized catheterization assessment; Diagnostic Test
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 12 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Severe Aortic Stenosis
Interventions: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR), Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI); Device · Procedure
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: Not listed
Enrollment: 1,746 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 65
States / cities: Phoenix, Arizona • Hollywood, California • La Jolla, California + 55 more

Conditions: Hypertrophic Cardiomyopathy
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Coronary Artery Disease
Interventions: Vessel Fractional Flow Reserve; Diagnostic Test
Lead sponsor: Erasmus Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects
Interventions: CK-3773274 - Granules in Capsule, Placebo - Granules in Capsule, CK-3773274 - Tablets; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Aortic Valve Stenosis
Interventions: Not listed
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Dallas, Texas • Plano, Texas

Conditions: Coarctation of Aorta, Aortic Stenosis, Cardiac Hypertrophy
Interventions: Echocardiogram, Serology; Procedure · Biological
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 18 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Cardiomyopathy, Hypertrophic Obstructive
Interventions: CT-G20, Placebo; Drug
Lead sponsor: Celltrion; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York

Conditions: Coronary Artery Disease, Myocardial Infarction, Coronary Disease, Coronary Stenosis, Angina Pectoris, Chest Pain
Interventions: Not listed
Lead sponsor: Angiowave Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Williams Beuren Syndrome, Williams Syndrome, Williams Beuren Region Duplication, Dup7
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2045
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Utility of Exercise-induced N-terminal (NT) Pro-brain Natriuretic Peptide Levels in Predicting Prognosis in Asymptomatic Aortic Stenosis

COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

The Promus Element Rewards Study

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Vitamin D Metabolism and the Williams Syndrome

Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem

FFR vs. icECG in Coronary Bifurcations

Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias

Deep Learning Enhanced Detection of Aortic Stenosis - The DETECT-AS-Diagnostic Study

ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis

Correlation Between an Impedance Cardiography Test for Decompensation and the Development of Left Ventricular Replacement Fibrosis

CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material

Defining Exercise Hemodynamics and Function After Transcatheter Aortic Valve Replacement (DEFINE-TAVR) Study.

Serp-1 for the Treatment of Acute Coronary Syndrome

Predicting Pediatric Pulmonary Vein Stenosis Outcomes Using Data Acquired During a Cardiac Catheterization

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

Sleep Apnea and Hypertrophic Cardiomyopathy (HCM)

Fast Assessment of STenosis Severity- FASTII Study

A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

Improving Echo Measurements in the Diagnosis of Aortic Stenosis

Cardiac Remodeling and Circulating Biomarkers in Pediatric Left Ventricular Pressure Loading Lesions

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy

CERROS Pilot Study

Characterization and Natural History of Williams Syndrome and Other Chromosome 7q11.23 Variants